Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metabolic Syndrome Reimbursement Forecast: Outlook Remains Cloudy

Executive Summary

In the near term, the best prospect for establishing a favorable reimbursement climate for metabolic syndrome may be to focus on treating comorbidities

You may also be interested in...



Disease Awareness Ads Increase, Along With Firms’ Need For Clarity From FDA

Industry would like greater clarification from FDA on appropriate disease awareness advertising when the agency finalizes its draft guidance

Disease Awareness Ads Increase, Along With Firms’ Need For Clarity From FDA

Industry would like greater clarification from FDA on appropriate disease awareness advertising when the agency finalizes its draft guidance

Sanofi-Aventis Acomplia Faces Good Reception From Physicians And Payers

Acomplia'schances of gaining acceptance as treatment for metabolic syndrome are improved by its effects on a range of the disease's comorbidities, according to Decision Resources analyst Donny Wong

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel